Last year, selumetinib, a small molecule MEK inhibitor which has been proven to decrease tumor volume of plexiform neurofibromas in children with NF1 was approved by US Food and Drug Administration to treat congenital and inoperable plexiform neurofibromas in children with NF1 [14]. The gene discussed is MAP2K7; the disease is plexiform neurofibroma.